Rocket Pharmaceuticals

RCKT

Market cap $356M

3.29 USD

+0.19

6.13%

At close Updated Nov 26, 4:00 PM EST

Pre-market

After hours

3.30

+0.01

0.3%

1 day

6.13%

5 days

12.29%

1 month

-16.5%

3 months

-2.95%

6 months

41.2%

Year to date

-74.14%

1 year

-76.68%

5 years

-89.73%

10 years

-93.07%

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299

Healthcare Biotechnology